Abstract
Nanoscience is the study of properties and characteristics that are unique to the nanoscale and pharmaceutical nanoscience is the application of the ensuing knowledge to the development of pharmaceuticals. Materials properties residing at the nanoscale have been found to offer a number of pharmaceutical products advanced functionality. Nanoparticles are fabricated from various chemistries, e.g. polymer-drug conjugates, self-assembled polymers, self-assembled low molecular weight amphiphiles, silica, crystalline iron salts, hydrophobic polymer nanoprecipitates and drug nanocrystals. Principally, with nano-enabled entities, there is unprecedented control of the in vivo fate of the drug compound and the science has subsequently already led to a number of approved products, e.g. Doxil, Ambisome and Abraxane with others in clinical development. As well as being able to control the biodistribution of drug compounds, emerging applications of pharmaceutical nanoscience include the use of nanofabricated materials for regenerative medicine and their application in diagnostic imaging.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cortes J, Saura C (2010) Nanoparticle albumin-bound (nab (TM))-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer. Eur J Cancer Suppl 8:1–10
Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464:1067–1070
Doshi N, Mitragotri S (2010) Macrophages recognize size and shape of their targets. PLos One 5:e10051
Duncan R (2003) The dawning era of polymer therapeutics. Nat Rev Drug Discov 2:347–360
Ferrari M (2008) Nanogeometry: beyond drug delivery. Nat Nanotechnol 3:131–132
Gabizon AA (2001) Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 19:424–436
Gabizon A, Shmeeda H, Barenholz Y (2003) Pharmacokinetics of pegylated liposomal doxorubicin—review of animal and human studies. Clin Pharmacokinet 42:419–436
Gratton SE, Ropp PA, Pohlhaus PD, Luft JC, Madden VJ, Napier ME, DeSimone JM (2008) The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci USA 105:11613–11618
Hrkach J, Von Hoff D, Ali MM, Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo M, Horhota A, Low S, McDonnell K, Peeke E, Retnarajan B, Sabnis A, Schnipper E, Song JJ, Song YH, Summa J, Tompsett D, Troiano G, Hoven TV, Wright J, LoRusso P, Kantoff PW, Bander NH, Sweeney C, Farokhzad OC, Langer R, Zale S (2012) Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 4:128ra39
Lalatsa A, Lee V, Malkinson JP, Zloh M, Schatzlein AG, Uchegbu IF (2012a) A prodrug nanoparticle approach for the oral delivery of a hydrophilic peptide, leucine(5)-enkephalin, to the brain. Mol Pharm 9:1665–1680
Lalatsa A, Schatzlein AG, Mazza M, Le TB, Uchegbu IF (2012b) Amphiphilic poly(l-amino acids)—new materials for drug delivery. J Control Release 161:523–536
Lee JW, Amantea MA, Francis PA, Navarro EE, Bacher J, Pizzo PA, Walsh TJ (1994) Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother 38:713–718
Mayes E, Douek M, Pankhurst QA (2012) Surgical magnetic systems and tracers for cancer staging. In: Thanh NTK (ed) Magnetic nanoparticles: from fabrication to clinical applications. CRC Press, Boca Raton, p 129, 541–556
Mazza M, Notman R, Anwar J, Rodger A, Hicks M, Parkinson G, McCarthy D, Daviter T, Moger J, Garrett N, Mead T, Briggs M, Schatzlein AG, Uchegbu IF (2013) Nanofiber-based delivery of therapeutic peptides to the brain. ACS Nano 7:1016–1026
Mitragotri S (2009) In drug delivery, shape does matter. Pharm Res 26:232–234
Paal K, Muller J, Hegedus L (2001) High affinity binding of paclitaxel to human serum albumin. Eur J Biochem 268:2187–2191
Siew A, Le H, Thiovolet M, Gellert P, Schatzlein A, Uchegbu I (2012) Enhanced oral absorption of hydrophobic and hydrophilic drugs using quaternary ammonium palmitoyl glycol chitosan nanoparticles. Mol Pharm 9:14–28
Uchegbu IF, Siew A (2013) Nanomedicines and nanodiagnostics come of age. J Pharm Sci 102:305–310
Veronese FM (2009) PEGylated protein drugs: basic science and clinical applications. Birkhauser, Basel
Walsh TJ, Yeldandi V, McEvoy M, Gonzalez C, Chanock S, Freifeld A, Seibel NI, Whitcomb PO, Jarosinski P, Boswell G, Bekersky I, Alak A, Buell D, Barret J, Wilson W (1998) Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother 42:2391–2398
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Uchegbu, I.F. (2013). Introduction. In: Uchegbu, I., Schätzlein, A., Cheng, W., Lalatsa, A. (eds) Fundamentals of Pharmaceutical Nanoscience. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9164-4_1
Download citation
DOI: https://doi.org/10.1007/978-1-4614-9164-4_1
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-9163-7
Online ISBN: 978-1-4614-9164-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)